Cargando…
Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis
Vancomycin is commonly used to treat methicillin‐resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Previous Vancomycin Consensus Guidelines recommended targeting trough concentrations but the 2020 Guidelines suggest monitoring vancomycin area under the curve (AUC) give...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481691/ https://www.ncbi.nlm.nih.gov/pubmed/35869689 http://dx.doi.org/10.1002/phar.2722 |
_version_ | 1784791319510515712 |
---|---|
author | Abdelmessih, Emily Patel, Nandini Vekaria, Janaki Crovetto, Brynna SanFilippo, Savanna Adams, Christopher Brunetti, Luigi |
author_facet | Abdelmessih, Emily Patel, Nandini Vekaria, Janaki Crovetto, Brynna SanFilippo, Savanna Adams, Christopher Brunetti, Luigi |
author_sort | Abdelmessih, Emily |
collection | PubMed |
description | Vancomycin is commonly used to treat methicillin‐resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Previous Vancomycin Consensus Guidelines recommended targeting trough concentrations but the 2020 Guidelines suggest monitoring vancomycin area under the curve (AUC) given the reduced risk of acute kidney injury (AKI) at similar levels of efficacy. This meta‐analysis compares vancomycin‐induced AKI incidence using AUC‐guided dosing strategies versus trough‐based monitoring. Literature was queried from Medline (Ovid), Web of Science, and Google Scholar from database inception through November 5, 2021. Interventional or observational studies reporting the incidence of vancomycin‐induced AKI between AUC‐ and trough‐guided dosing strategies were included. In the primary analysis, the Vancomycin Consensus Guidelines definition for AKI was used if reported; otherwise, the Risk, Injury, and Failure; and Loss, and End‐stage kidney disease (RIFLE) or Kidney Disease Improving Global Outcomes (KDIGO) definitions were used. The incidence of nephrotoxicity was evaluated between the two strategies using a Mantel–Haenszel random‐effects model, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Subgroup analyses for adjusted ORs and AKI definitions were performed. Heterogeneity was identified using Cochrane's Q test and I (2) statistics. A total of 10 studies with 4231 patients were included. AUC‐guided dosing strategies were associated with significantly less vancomycin‐induced AKI than trough‐guided strategies [OR 0.625, 95% CI (0.469–0.834), p = 0.001; I (2) = 25.476]. A subgroup analysis of three studies reporting adjusted ORs yielded similar results [OR 0.475, 95% CI (0.261–0.863), p = 0.015]. Stratification by AKI definition showed a significant reduction in AKI with the Vancomycin Consensus Guidelines definition [OR 0.552, 95% CI (0.341–0.894), p = 0.016] but failed to find significance in the alternative definitions. Area under the curve‐guided dosing strategies are associated with a lower incidence of vancomycin‐induced AKI versus trough‐guided dosing strategies (GRADE, low). Limitations included the variety of AKI definitions and the potential for confounding bias. |
format | Online Article Text |
id | pubmed-9481691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94816912022-10-14 Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis Abdelmessih, Emily Patel, Nandini Vekaria, Janaki Crovetto, Brynna SanFilippo, Savanna Adams, Christopher Brunetti, Luigi Pharmacotherapy Review of Therapeutics Vancomycin is commonly used to treat methicillin‐resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Previous Vancomycin Consensus Guidelines recommended targeting trough concentrations but the 2020 Guidelines suggest monitoring vancomycin area under the curve (AUC) given the reduced risk of acute kidney injury (AKI) at similar levels of efficacy. This meta‐analysis compares vancomycin‐induced AKI incidence using AUC‐guided dosing strategies versus trough‐based monitoring. Literature was queried from Medline (Ovid), Web of Science, and Google Scholar from database inception through November 5, 2021. Interventional or observational studies reporting the incidence of vancomycin‐induced AKI between AUC‐ and trough‐guided dosing strategies were included. In the primary analysis, the Vancomycin Consensus Guidelines definition for AKI was used if reported; otherwise, the Risk, Injury, and Failure; and Loss, and End‐stage kidney disease (RIFLE) or Kidney Disease Improving Global Outcomes (KDIGO) definitions were used. The incidence of nephrotoxicity was evaluated between the two strategies using a Mantel–Haenszel random‐effects model, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Subgroup analyses for adjusted ORs and AKI definitions were performed. Heterogeneity was identified using Cochrane's Q test and I (2) statistics. A total of 10 studies with 4231 patients were included. AUC‐guided dosing strategies were associated with significantly less vancomycin‐induced AKI than trough‐guided strategies [OR 0.625, 95% CI (0.469–0.834), p = 0.001; I (2) = 25.476]. A subgroup analysis of three studies reporting adjusted ORs yielded similar results [OR 0.475, 95% CI (0.261–0.863), p = 0.015]. Stratification by AKI definition showed a significant reduction in AKI with the Vancomycin Consensus Guidelines definition [OR 0.552, 95% CI (0.341–0.894), p = 0.016] but failed to find significance in the alternative definitions. Area under the curve‐guided dosing strategies are associated with a lower incidence of vancomycin‐induced AKI versus trough‐guided dosing strategies (GRADE, low). Limitations included the variety of AKI definitions and the potential for confounding bias. John Wiley and Sons Inc. 2022-08-05 2022-09 /pmc/articles/PMC9481691/ /pubmed/35869689 http://dx.doi.org/10.1002/phar.2722 Text en © 2022 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review of Therapeutics Abdelmessih, Emily Patel, Nandini Vekaria, Janaki Crovetto, Brynna SanFilippo, Savanna Adams, Christopher Brunetti, Luigi Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title | Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title_full | Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title_fullStr | Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title_full_unstemmed | Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title_short | Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta‐analysis |
title_sort | vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta‐analysis |
topic | Review of Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481691/ https://www.ncbi.nlm.nih.gov/pubmed/35869689 http://dx.doi.org/10.1002/phar.2722 |
work_keys_str_mv | AT abdelmessihemily vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT patelnandini vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT vekariajanaki vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT crovettobrynna vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT sanfilipposavanna vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT adamschristopher vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis AT brunettiluigi vancomycinareaunderthecurveversustroughonlyguideddosingandtheriskofacutekidneyinjurysystematicreviewandmetaanalysis |